SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing a sharp sell-off following the announcement that Marvell cancelled purchase orders due to an alleged breach of confidentiality triggered by recent public comments from the company's CFO. While the community remains deeply divided between those calling the stock a fundamental failure and others who view the dip as a tactical buying opportunity, the primary concern is the potential erosion of trust with future hyperscale partners.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as investors weigh strong AI and automotive growth potential against near-term headwinds like supply chain constraints and cautious analyst sentiment. The stock is a primary focus for the community, which remains divided on whether the current price represents a buying opportunity or a deeper structural decline.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as they await topline Phase 3 data from the HAELO trial, which the community sees as a potential validation for their in vivo CRISPR platform. Traders are actively debating the high short interest and the stock's susceptibility to a squeeze, with many weighing the clinical promise of a functional HAE cure against the broader volatility affecting the biotech sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares is experiencing massive volatility and bullish momentum driven by a strong semiconductor sector rally, fueled by earnings optimism and ongoing AI infrastructure spending. Investors are actively debating whether the current parabolic price action signifies a sustainable super-cycle or a speculative bubble, leading to intense sentiment clashes between bullish 'diamond hands' and traders betting on a sharp mean reversion.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is generating significant investor buzz as it makes its market debut, with the community highlighting its strategic backing from major players like Amazon and Dow to address the surging energy demands of AI data centers. Traders are actively debating the company's valuation and long-term potential compared to other modular nuclear reactor peers, fueled by high initial demand and its positioning as a key player in the clean energy infrastructure space.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant investor interest as it approaches a high-profile oral presentation of pancreatic cancer data at Digestive Disease Week, which the community views as a critical catalyst for the stock. Traders are actively accumulating shares, citing strong scientific momentum and the company's progress in expanding global clinical trials.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is gaining significant momentum as investors digest a new share buyback program and the upcoming elimination of pattern day trading (PDT) restrictions. The community is actively debating the stock's valuation relative to its growth potential, with many discussing potential short squeeze setups and comparing its market positioning to peers like Robinhood.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is currently seeing significant investor attention driven by positive Phase 3 acne data and the potential for its FASN inhibitor denifanstat as a cornerstone MASH treatment. The community is actively debating the company's valuation, the strategic shift toward combination therapies, and the high probability of a future buyout given the surge in M&A activity within the metabolic disease sector.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing intense volatility and social media discussion driven by frequent trading halts and speculation regarding its business model and recent strategic management changes. The community remains deeply divided, with some traders focused on momentum and potential short-squeeze dynamics, while others express significant skepticism about the company's financial structure and long-term outlook.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors anticipate upcoming product news at the XRP Las Vegas conference, fueling community enthusiasm about the project's potential in the payments sector. While some traders discuss taking short-term gains, many long-term holders are actively accumulating, viewing the current price as an entry opportunity for a multi-year investment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Paysign, Inc. (NASDAQ:PAYS) Short Interest Up 36.7% in March

Paysign, Inc. (NASDAQ:PAYS - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,289,773 shares...

Paysign to Host First Quarter 2026 Earnings Call

Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, will discuss first quarter 2026 earnings at 5:00 p.m. Eastern time on Tuesday...

Paysign (NASDAQ:PAYS) Issues FY 2026 Earnings Guidance

Paysign (NASDAQ:PAYS) updated its FY 2026 earnings guidance. The company provided EPS guidance of 0.210-0.260 for the period, compared to the consensus estimate of 0.240. The company also issued revenue guidance of $106.5 millionillion-$110.5 millionillion, compared to the consensus estimate of...

Paysign (NASDAQ:PAYS) Updates Q1 2026 Earnings Guidance

Paysign (NASDAQ:PAYS) updated its first quarter 2026 earnings guidance. The company provided EPS guidance of 0.070-0.080 for the period, compared to the consensus estimate of 0.070. The company also issued revenue guidance of $27.0 millionillion-$27.5 millionillion, compared to the consensus...

Paysign (NASDAQ:PAYS) Rating Increased to Buy at Wall Street Zen

Wall Street Zen raised shares of Paysign from a "hold" rating to a "buy" rating in a research note on Monday...

Here's How Much $100 Invested In PaySign 10 Years Ago Would Be Worth Today

DA Davidson Reiterates Buy Rating for Paysign (NASDAQ:PAYS)

DA Davidson reissued a "buy" rating and issued a $9.00 price target on shares of Paysign in a research note on Thursday...

Why Paysign Stock Is Skyrocketing Today

Key PointsPaysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations...

Paysign (NASDAQ:PAYS) Given New $11.00 Price Target at Lake Street Capital

Lake Street Capital increased their price objective on shares of Paysign from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday...

Healthcare Payments Player Surges as Growth Engine Accelerates

The intersection of healthcare and financial technology continues to gain traction as providers and patients alike seek more efficient ways to manage rising medical costs. Patient affordability programs, in particular, are emerging as a critical piece of the healthcare ecosystem, helping bridge the gap between treatment access and out-of-pocket expenses while creating scalable opportunities for companies operating at the center of the payment flow.Shares of Paysign, Inc. (NASDAQ: PAYS) are moving sharply higher Tuesday morning, after the company reported strong fourth quarter and full-year ...

Paysign, Inc. engages in the provision of prepaid card programs and processing services for corporate, consumer & government applications. It specializes in corporate incentive products, payroll cards, general purpose re-loadable cards, and travel cards. The firm markets prepaid solutions through its PaySign brand. The company was founded by Mark R. Newcomer and Daniel H. Spencer on August 24, 1995 and is headquartered in Henderson, NV.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.07	--	--	N/A
Q4 '25	$0.02	$0.02	--	EXPECTED
Q3 '25	$0.02	$0.04	100.00%	BEAT
Q2 '25	$0.04	$0.02	-42.86%	MISSED
Q1 '25	$0.02	$0.05	199.99%	BEAT

PAYS
PaySign Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest PAYS News

PAYSPaySign Inc